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Functional characterization 
of ABCB4 mutations found in 
progressive familial intrahepatic 
cholestasis type 3
Hyo Jin Park1,*, Tae Hee Kim1,*, So Won Kim2, Shin Hye Noh3, Kyeong Jee Cho3, Choe Choi3, 
Eun Young Kwon1, Yang Ji Choi1, Heon Yung Gee3 & Ji Ha Choi1
Multidrug resistance 3 (MDR3), encoded by the ATP-binding cassette, subfamily B, member 4 gene 
(ABCB4), localizes to the canalicular membrane of hepatocytes and translocates phosphatidylcholine 
from the inner leaflet to the outer leaflet of the canalicular membrane. Progressive familial intrahepatic 
cholestasis type 3 (PFIC3) is a rare hepatic disease caused by genetic mutations of ABCB4. In this study, 
we characterized 8 ABCB4 mutations found in PFIC3 patients, using in vitro molecular assays. First, we 
examined the transport activity of each mutant by measuring its ATPase activity using paclitaxel or 
phosphatidylcholine. Then, the pathogenic mechanisms by which these mutations affect MDR3 were 
examined through immunoblotting, cell surface biotinylation, and immunofluorescence. As a result, 
three ABCB4 mutants showed significantly reduced transport activity. Among these mutants, one 
mutation A364V, located in intracellular domains, markedly decreased MDR3 expression on the plasma 
membrane, while the others did not affect the expression. The expression of MDR3 on the plasma 
membrane and transport activity of A364V was rescued by a pharmacological chaperone, cyclosporin 
A. Our study provides the molecular mechanisms of ABCB4 mutations and may contribute to the 
understanding of PFIC3 pathogenesis and the development of a mutation-specific targeted treatment 
for PFIC3.
The liver is the one of the major organs responsible for the elimination of drugs and other xenobiotics from the 
body1. The ATP-binding cassette, subfamily B, member 4 gene (ABCB4), codes for human multidrug resistance 
3 (MDR3)2. MDR3 is mainly expressed on the canalicular membrane of hepatocytes and plays an important role 
in the protection of the liver through translocation of phosphatidylcholine from the inner leaflet to the outer 
leaflet of the canalicular membrane2,3. Progressive familial intrahepatic cholestasis type 3 (PFIC3) is caused by 
genetic mutations in ABCB44. PFIC denotes a group of rare hepatic diseases, and onset varies from the neonatal 
period to early adulthood, depending on the specific type of disease. PFIC patients are usually candidates for liver 
transplantation before adulthood, due to complications such as hepatic failure, liver cirrhosis, and hepatocellular 
carcinoma5. Recently, new approaches for the treatment of hepatic diseases resulting from canalicular transport 
defects, as occurs in PFIC, have been suggested, including inducing an increase in the expression of functional 
protein by using synthetic farnesoid X receptor ligands or pharmacological chaperones6.
To date, several studies have been conducted to identify and functionally characterize the ABCB4 muta-
tions found in PFIC3 patients, however, they do not include all the identified mutations7–12. A missense muta-
tion found in PFIC3 patients, I541F, was shown to decrease transport activity through reduction of membrane 
MDR3 expression, which could be functionally rescued by low temperature or cyclosporin A8,9. Some genetic 
variations of ABCB4 are associated with other hepatobiliary diseases such as obstetric cholestasis, cholelithiasis, 
drug-induced liver injury, and primary biliary cirrhosis13–18. Recently, we performed functional characterization 
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of the ABCB4 promoter variants and found that two common ABCB4 promoter haplotypes led to significantly 
decreased promoter activity. In addition, we identified nuclear factor-Y (NF-Y) as a possible transcriptional factor 
involved in the regulation of ABCB4 transcription19.
Previously, ABCB4 mutations were newly identified through direct sequencing, using genomic DNA sam-
ples from 68 PFIC3 patients7. The authors found 29 mutations in the coding region, including 23 missense, four 
nonsense, and two short insertion mutations. To evaluate the effect of these mutations on protein function, they 
mapped each variant on the predicted tertiary structure of MDR3, and found that 10 out of 29 mutations were 
located on transmembrane domains (TMs). In particular, TM 7, which may be required for the translocation of 
phosphatidylcholine, was most commonly affected. However, these studies did not perform a functional charac-
terization of mutations.
In the present study, we selected 8 missense mutations of ABCB4 that were first reported by Degiorgio et al.7 
and investigated the effect of each mutant on MDR3 transport activity or expression by using a range of in vitro 
assays such as a membrane vesicular adenosine triphosphatase (ATPase) assay, immunoblotting, surface bioti-
nylation assay, and immunofluorescence. Our study provides the molecular pathogenic mechanisms of ABCB4 
mutations, and our findings may contribute to the development of a new drug for the treatment of PFIC3 or other 
MDR3-deficiency related diseases.
Results
ABCB4 mutations examined in this study. We selected 8 missense mutations that were first reported by 
Degiorgio et al.7. Among the 29 ABCB4 mutations identified by Degiorgio et al.7, we excluded nonsense muta-
tions and mutations that were also found in other MDR3-deficient phenotypes or those that affect amino acid res-
idues, which are conserved in other ABC transporters, in particular, the MDR1 transporter, as these had already 
been investigated20–22. The 8 missense ABCB4 mutations examined in this study are listed in Table 1.
ABCB4 mutations affect transporter activity. To characterize the functional effects of the ABCB4 
mutations, we examined the transport activity of each mutant by measuring the ATPase activity using paclitaxel 
or phosphatidylcholine, which are known MDR3 substrates23,24 (Fig. 1). To exclude ATPase activity by other 
endogenous ABC transporters, such as MDR1, values for transport activity were obtained by subtracting the 
uptake in empty-vector-transfected cells from that in cells transfected with ABCB4 wild type or mutant-bearing 
vectors, at each paclitaxel or phosphatidylcholine concentration. Inhibition of transport by verapamil, a known 
inhibitor of MDR323, confirmed that the transport was MDR3-mediated (Supplementary Fig. S1). As a result, 
the paclitaxel-induced ATPase activity was significantly reduced in membrane vesicles, which expressed three 
ABCB4 mutations: A364V, A737V, and A1193T (Fig. 1a). Table 2 shows the paclitaxel Vmax and Km values for 
the ABCB4 wild type or mutants. We observed that the average value of Vmax/Km for three ABCB4 mutants was 
significantly reduced compared to that of the ABCB4 wild type. This resulted from a reduced Vmax. MDR3 shows 
phosphatidylcholine-induced ATPase activity25; therefore, we additionally performed the ATPase assay using 
cDNA positiona
Amino acid 
substitutionb
Predicted 
domain
Mutation 
Tasterc PolyPhen2d SIFTe PROVEANf
Frequencies in the 
dbSNP databaseg
Frequencies in the 
ExAC databaseh
Frequencies in 
the EVS databasei
c.749G > C p.A250P ICD2 DC 0.959 Dam Del No No No
c.857C > T p.A286V ICD2 DC 0.990 Dam Del No 2/121360 (no homozygote) No
c.1069T > C p.F357L ICD3 DC 0.101 Dam Del No No No
c.1091C > T p.A364V ICD3 DC 0.997 Dam Del No No No
c.1424T > C p.V475A NBD-NH2 ter DC 0.610 Dam Del No No No
c.2144C > T p.T715I TM2 DC 0.026 Tol Neu rs138773456 (MAF = 0.0002)
68/121370 (no 
homozygote)
AA/AG/
GG = 0/10/6493
c.2210C > T p.A737V EC4 SNP 0.009 Dam Neu rs147134978 (MAF, NA)
3/121404 (no 
homozygote)
AA/AG/
GG = 0/1/6502
c.3577G > A p.A1193T
NBD-
COOH 
ter
DC 0.966 Dam Del No No No
Table 1.  ABCB4 mutations examined in this study. Abbreviations are as follows: Dam, damaging; DC, 
disease causing; Del, deleterious; EC, extracellular loop; ICD, intracellular domain; MAF, minor allele 
frequency; NA, not available; NBD, nucleotide binding domain; Neu, neutral; No, no data; SNP, single 
nucleotide polymorphism; ter, terminal end; tol, tolerated; TM, transmembrane domain. acDNA position is 
numbered according to human cDNA reference sequence NM_018849.2 (ABCB4); + 1 corresponds to the A 
of ATG translation initiation codon. bAmino acid residue is numbered according to human protein reference 
sequence NP_061337.1. cMutation taster (http://www.mutationtaster.org/). dPolyPhen-2 prediction score 
HumVar ranges from 0 to 1.0; 0 = benign, 1.0 = probably damaging (http://genetics.bwh.harvard.edu/pph2/). 
eSorting Intolerant From Tolerant (http://sift.jcvi.org/www/SIFT_chr_coords_submit.html). fProtein Variation 
Effect Analyzer (http://provean.jcvi.org/seq_submit.php). gdbSNP database (http://www.ncbi.nlm.nih.gov/
SNP). hExome Aggregation Consortium browser (http://exac.broadinstitute.org/). iExome Variant Server 
(http://evs.gs.washington.edu/EVS/).
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phosphatidylcholine, for the three mutants: A364V, A737V, and A1193T. We observed a significant decrease in 
their ATPase activities and this is consistent with the results obtained using paclitaxel (Fig. 1b).
The effect of mutations on the expression level of MDR3. To examine the mechanisms through 
which ABCB4 mutations alter the transport activity, we investigated MDR3 expression levels of the mutants 
on the plasma membrane by immunofluorescence and cell surface biotinylation. Upon overexpression of wild 
type and mutant ABCB4 in HEK-293T cells, among the three ABCB4 mutants that showed decreased transport 
Figure 1. Effect of ABCB4 mutants on transport activity. Inside-out membrane vesicles were prepared after 
transfection of ABCB4 wild type or mutant-bearing plasmids into HEK-293T cells, and the ATPase activity 
induced by either paclitaxel (a) or phosphatidylcholine (b) was measured. The X-axis represents paclitaxel or 
phosphatidylcholine concentration. The Y-axis represents the amount of inorganic phosphate that was produced 
by the ATPase activity of MDR3. Data shown represent mean ± SD from five independent experiments and 
analyzed by one-way analysis of variance followed by Dunnett’s two-tailed test. *P < 0.05, **P < 0.01, ***P < 0.001 
vs. wild type (WT).
Vmax (nmol 
mg−1 per min) Km (μM)
Vmax/Km ratio (nmol 
mg−1 min−1 per μM)
WT 72.27 ± 15.60 1.11 ± 0.14 65.75 ± 15.39
A250P 62.51 ± 14.20 1.27 ± 0.15 49.49 ± 10.64
A286V 72.97 ± 17.00 1.03 ± 0.21 72.65 ± 17.20
F357L 53.41 ± 11.71 1.10 ± 0.18 48.06 ± 5.02
A364V 44.29 ± 14.94* 1.35 ± 0.22 33.81 ± 13.21**
V475A 59.81 ± 15.50 1.20 ± 0.21 49.78 ± 8.95 
T715I 58.64 ± 16.33 1.13 ± 0.21 51.90 ± 12.48
A737V 38.63 ± 8.54** 1.12 ± 0.15 34.88 ± 9.74**
A1193T 46.58 ± 5.47* 1.18 ± 0.19 40.05 ± 6.39*
Table 2.  Kinetic values of ABCB4 wild type or its mutants in the ATPase assay using paclitaxel. Data 
(mean ± SD) were from 5 separate experiments. *P < 0.05, **P < 0.01; multiple comparisons were performed using 
one-way analysis of variance followed by Dunnett’s two-tailed test. The values of wild type were used as control.
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activities, A737V and A1193T was mainly expressed on the plasma membrane like ABCB4 wild type (Fig. 2). 
However, we observed that the MDR3 expression of A364V on the plasma membrane was decreased and a large 
of fraction of MDR3 was present in the endoplasmic reticulum or Golgi (Fig. 2). In addition, cell surface biotiny-
lation demonstrated that A364V mutant had significantly decreased MDR3 expression on the plasma membrane 
by 30% as compared to that in the wild type vector transfected cells (Fig. 3). The surface expression level of A737V 
was comparable with that of the wild type, and that of A1193T seemed to decrease, but it was not statistically sig-
nificant (Fig. 3), even though their transport activities were decreased. Based on these results, we suspected that 
A364V mutant had folding or trafficking defects. Proteins with trafficking defects usually undergo degradation 
by proteasome or lysosome, we examined this for A364V. We observed that MDR3 expression of A364V was 
significantly increased by 116% and 115%, after treatment with an inhibitor of proteasomal proteolysis, MG132 
(Fig. 4a), and an inhibitor of lysosomal degradation, bafilomycin A1, respectively (Fig. 4b). While, MDR3 expres-
sion of the wild type vector transfected cells was not as much as that for A364V, expression was increased by 46% 
Figure 2. Effect of ABCB4 mutants on subcellular localization. HEK-293T cells were transfected with 
ABCB4 wild type or mutant plasmids. Cells were fixed and permeabilized with methanol, and immunostained 
with anti-MDR3, and an endoplasmic reticulum maker BiP or a Golgi marker Gigantin antibodies. Scale bars, 
10 μ m.
Figure 3. Effect of ABCB4 mutants and cyclosporin A (CsA) on the surface expression of MDR3. (a) HEK-
293T cells transfected with ABCB4 wild type or mutant plasmids, and surface biotinylated. CsA was treated at 
10 μ M for 24 hours. Absence of the cytosolic protein aldolase A in the biotinylated fraction confirms cell surface 
protein-specific labeling in each experiment. (b) Quantification of surface expression of MDR3. Bar graphs 
represent band density of surface biotinylated MDR3 compared to the wild type ABCB4 and error bars indicate 
the SD for three independent experiments. *P < 0.05, Student’s t test.
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and 18% after treatment with MG132 and bafilomycin A1, respectively (Fig. 4). These data suggest that A364V 
is vulnerable to intracellular degradation, and the decreased MDR3 expression of this mutant might be a result 
of proteasomal or lysosomal degradation. For the five mutations that showed similar transport activities as com-
pared to the wild type, their MDR3 expression levels were comparable with those of the wild type (Supplementary 
Fig. S2).
The effect of cyclosporin A on the expression and function of a trafficking-defective mutant. A 
previous study by Gautherot et al.9 showed that a trafficking-defective mutation of ABCB4 was functionally res-
cued by cyclosporin A. In their study, cyclosporin A produced a dose-dependent increase in MDR3 expression. 
Therefore, we tested whether a trafficking-defective mutant of ABCB4, A364V could be rescued by cyclosporin 
A. To examine it, we performed cell surface biotinylation after cells were treated with 10 μ M cyclosporine A. As 
a result, we observed that cyclosporin A significantly increased MDR3 expression levels of A364V (Fig. 3). Our 
finding was similar to those of a previous study9. Then, to examine the effect of cyclosporin A on the transport 
activity of A364V, membrane vesicular ATPase assays were performed after treatment with cyclosporin A. We 
found that cyclosporin A increased the transport activity of this mutant significantly in the ATPase assays using 
paclitaxel or phosphatidylcholine (Fig. 5).
Discussion
Recently, screening of genomic DNA samples from 68 PFIC3 patients identified 29 mutations, 25 of which 
were novel7. In this study, authors examined the effect of each mutation on the protein tertiary structure using 
a three-dimensional model of MDR3. MDR3 consists of twelve TMs, six intracellular domains (ICDs), six 
extracellular loops (ECs), and a linker peptide connecting the N-terminal to the C-terminal transmembrane 
domain-nucleotide binding domain (TMD-NBD). Most mutations were located in the NBDs, TMs, or ICDs, 
which may be involved in substrate binding and translocation, coupling the energy from ATP hydrolysis to sub-
strate transport, and the conformational change involved in substrate extrusion. Ten mutations were located in 
TMs, nine in ICDs, and eight in NBDs. However, functional characterization of each mutant was not performed 
in this previous study.
The present study was conducted to functionally characterize the ABCB4 mutations reported in the previous 
study by Degiorgio et al.7. Among 29 ABCB4 mutations, we selected 8 missense mutations. Then, we measured 
the transport activity of each mutant indirectly by ATPase assays using paclitaxel or phosphatidylcholine. we 
found that three mutants showed significantly decreased transport activities, whereas the other five mutants had 
similar transport activities compared to that of the wild type. These results are unexpected, however, two mutants, 
A250P and F357L, were initially identified as in cis with M630V and T775M, respectively7, suggesting that F357L 
or A250P is probably not sufficient to cause loss-of-function of MDR3 transport activity by itself. In addition, the 
pathogenicity of A286V, V475A and T715I may depend on the trans-associated mutation, as shown for NPHS2 
R229Q26. In other words, these alleles lead to a disease phenotype only when it is associated specifically with 
Figure 4. Effect of MG132 or bafilomycin A1 on MDR3 expression. MDR3 expression was investigated after 
transfection with ABCB4 wild type or A364V mutant plasmids. Immunoblotting was performed after treatment 
with MG132 (a) or bafilomycin A1 (b). Data shown represent mean ± SD from three independent experiments 
and analyzed by one-way analysis of variance followed by Dunnett’s two-tailed test. **P < 0.01 vs. expression of 
A364V without MG132 or bafilomycin A1 treatment.
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certain ABCB4 mutations. For three mutants which exhibited decreased transport activities, we found that the 
reduced expression for A364V, located in the ICDs, might be due to proteasomal and lysosomal degradation. In 
the case of A737V and A1193T, the results from the cell surface biotinylation, immunoblotting, and immunofluo-
rescence experiments indicated that decreased transport activity of these mutants did not result from the reduced 
MDR3 expression on the plasma membrane. Recently Gautherot et al.27 reported that two ABCB4 mutants, T34M 
and R47G, resulted in abnormal phosphorylation of its N-terminal domain, leading to decreased secretion of 
phosphatidylcholine while the targeting to the plasma membrane of those mutants was comparable with the wild 
type ABCB4. Further in vitro study would be necessary to elucidate the cause of decreased transport activity of 
A737V and A1193T.
Most of the ABC transporters are expressed on the plasma membrane of cells, where they transport various 
substrates. Serious human disease can occur if the transporters are not expressed on the cell surface properly due 
to folding defects28. The correction of folding defects caused by specific mutations, through alteration of intracel-
lular environment or addition of pharmacological compounds, is a valuable approach for the treatment of some 
genetic diseases. For example, ∆ F508 of cystic fibrosis conducting regulator (CFTR), the most common mutation 
in patients with cystic fibrosis, impairs CFTR folding29. Many studies reported that folding and trafficking defects 
of ∆ F508 could be partially rescued by various modulators such as thapsigargin, sodium 4-phenylbutyrate, and 
aminoarylthiazoles or by overexpression of heat shock protein 70 or Golgi reassembly stacking proteins9,29–31. In 
the case of the other ABC transporters, a few approaches have focused on correcting trafficking-defective muta-
tions. For example, a processing mutant of ABCB1 could also be rescued by substrates or modulators of MDR12,29. 
In particular, it has been shown that the pharmacological chaperone cyclosporin A, a known inhibitor of MDR1, 
increases the levels of total and matured protein of MDR1 by stabilizing the mutant protein32. Recently, two sep-
arate studies reported that an ABCB4 trafficking-defective mutation, I541F, could be rescued by low temperature 
or addition of cyclosporin A, which could correct the folding defects introduced by this mutation8,9. Similarly, in 
this study, we found that the trafficking defect induced by the mutation A364V could be rescued by cyclosporin 
A. We also found that the transport activity of this mutant was restored with cyclosporin A.
In some PFIC3 patients with mild symptoms, therapy with ursodeoxycholic acid could be effective5. However, 
most PFIC3 patients are ultimately candidates for liver transplantation. Although solid organ transplantation, 
including liver transplantation, is regarded as one of the most significant advances in medical science, it still faces 
various challenges such as organ unavailability, postoperative complications, and high costs33,34. In the case of 
pediatric liver transplantation, there are additional problems such as growth retardation due to prolonged steroid 
exposure, lower physical and psychosocial function after liver transplantation, graft loss, and preoperative mal-
nutrition35,36. The identification of successful mechanism-based drugs for the treatment of PFIC3 is necessary to 
improve the quality of life in pediatric PFIC3 patients.
The present study has a limitation in that the transport activity or phosphatidylcholine flippase activity was 
not measured directly. ABC transporters, including MDR3, use ATP as an energy source to transport their sub-
strates37; we measured this ATPase activity and thus, indirectly evaluated the transporter activities of wild type 
and mutant ABCB4. However, functional study of transporters using the ATPase assay has been reported previ-
ously38,39. In particular, Kwak et al.39 investigated the transport activity of MDR1 using two different methods, 
ATPase assays and direct transport assays using rhodamine 123 and reported that the results from the ATPase 
assays were comparable with those from the direct assays.
In conclusion, we have characterized a few ABCB4 mutations found in PFIC3 patients and found that the 
A364V, A737V, and A1193T mutants show significantly decreased transport activities, as measured indirectly 
Figure 5. Effect of CsA on the transport activity of the mutant A364V. Membrane vesicular ATPase assays 
were performed using paclitaxel (a) or phosphatidylcholine (b) after treatment with CsA. Data shown represent 
mean ± SD from three independent experiments, and the P values for comparison between the results obtained 
before and after CsA treatment, were calculated using Student’s t test. *P < 0.05, ***P < 0.001 vs. transport activity 
of A364V without CsA treatment.
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using the ATPase assay. The mechanisms by which these ABCB4 mutants may decrease transport activities were 
determined in this study: A364V, a mutant in the ICDs, was trafficking-defective, while others did not affect 
MDR3 expression on the plasma membrane. We reported that both the expression of MDR3 on the plasma mem-
brane and the transport activity of this trafficking-defective mutant could be rescued by a cyclosporin A. To our 
knowledge, this is the first study to functionally characterize a large number of ABCB4 mutations. The functional 
characterization of ABCB4 mutations could enable development of mutation-specific treatment regimens for 
PFIC3 patients in the future.
Methods
Construction of ABCB4 plasmids. To construct a plasmid containing a wild type ABCB4 gene, the 
BC_042531 vector was purchased (Thermo Fisher Scientific Inc., Waltham, MA, USA) and subcloned into the 
pcDNA3.1(+ ) vector. Mutant-bearing plasmids were produced using QuikChange® II Site-Directed Mutagenesis 
Kit (Agilent Technologies, Santa Clara, CA, USA). Nucleotide location numbers were assigned according to the 
ABCB4 mRNA sequence (GenBank accession number: NM_018849.2). Supplementary Table S1 lists primers 
used in this study.
Membrane vesicle preparation. Membrane vesicles were prepared according to a previously described 
method40. ABCB4 wild type or mutant-bearing plasmids were transfected into human embryonic kidney-293T 
(HEK-293T) cells using the Calcium Phosphate Transfection Kit (Life Technologies Corporation, Carlsbad, 
CA, USA). Forty-eight hours later, cells were harvested and subjected to nitrogen cavitation at 350 pounds per 
square inch, for 15 min. After transfer into a tube containing 0.5 M EDTA, centrifugation was performed twice 
at 1,900 × g, for 10 min each time, to obtain the supernatant. The membrane vesicle fractions were collected by 
sucrose density gradient centrifugation at 1,000,000 × g for 90 min and suspended in buffer containing 250 mM 
sucrose and 50 mM Tris.
ATPase assay. The vanadate-sensitive ATPase activity was measured using the SensoLyte® MG Phosphate 
Assay Kit (AnaSpec, Fremont, CA, USA) for paclitaxel or phosphatidylcholine transport, according to a pre-
viously described method39. First, membrane vesicles (4 μ g/well) were prepared in 4 mM MgCl2, 5 mM 
3-(N-morpholino)-propanesulfonic acid-Tris (pH 7.0), 4 mM ATP, and various concentrations of paclitaxel or 
phosphatidylcholine. For the inhibition assay, 150 or 400 μ M verapamil was added to each well. Finally, absorb-
ance was measured at 620 nm, using a microplate reader. ATPase activities were determined as the inorganic 
phosphate liberation, normalized by subtracting the activities of the mock vesicles, without the transfection of 
ABCB4 wild type or mutant-bearing plasmids.
Immunoblotting. The ABCB4 wild type or mutant-bearing plasmids were transfected into HEK-293T cells 
by using the Lipofectamine LTX and Plus reagents (Life Technologies). To examine the effect of MG132 or bafi-
lomycin A1 on ABCB4 mutants, cells were treated with 10 μ M MG132 or 0.1 mg/ml bafilomycin A1 24 h after 
transfection. To investigate the effect of cyclosporin A, cells were treated with 10 μ M cyclosporin A, 6 h after 
transfection. Thirty or forty-eight hours after transfection, immunoblotting was performed using the primary 
antibodies mouse anti-MDR3 antibody (Abcam, Cambridge, UK) or goat anti-β -actin antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). The intensity of each band was measured using ImageJ (National Institutes 
of Health, Bethesda, MD, USA).
Surface biotinylation assay. Biotinylation experiments were conducted using a Cell Surface Protein 
Isolation Kit (Thermo Fisher Scientific Inc.), performed according to the manufacturer’s protocol, using the cells 
obtained from transfection of the ABCB4 wild type or mutant-bearing plasmids into HEK-293T cells. To examine 
the effect of cyclosporin A on ABCB4 mutants, cells were treated with 10 μ M cyclosporin A, 6 h after transfec-
tion. A rabbit polyclonal anti-Na+/K+ ATPase α -1 (EMD Millipore, Billerica, MA, USA) and a goat polyclonal 
anti-Aldolase A (Santa Cruz Biotechnology) antibodies were used as internal standards.
Immunofluorescence. For immunofluorescence, HEK-293T cells were grown on cover glasses, in a 24-well 
plate, and the ABCB4 wild type or mutant-bearing plasmids were transfected into HEK-293T cells. Twenty-four 
hours after transfection, cells were fixed and permeabilized with cold methanol for 10 min at − 20 °C, following 
which blocking was performed. To detect MDR3, cells were incubated overnight at 4 °C with the anti-MDR3 
and anti-BiP (Abcam) or anti-gagantin (Abcam) antibodies. After washing with PBS, Alexa Fluor® 488 rabbit 
anti-mouse IgG and Alexa Fluor® 594 goat anti-rabbit IgG (Life Technologies) were used as fluorophore-tagged 
secondary antibodies, and DAPI was used for nucleic acid staining. Confocal images were captured using a con-
focal laser scanning microscope, and the digital images were analyzed using an LSM Image Examiner (Carl Zeiss, 
Oberkochen, Germany).
Statistical analysis. Statistical analysis was performed using the GraphPad Prism 4.0 software package 
(GraphPad Software Inc., San Diego, CA, USA). The data shown in the ATPase assay, immunoblotting, and sur-
face biotinylation assay represent mean ± SD from more than three separate experiments. P values for compari-
son between the results obtained before and after cyclosporin A treatment were calculated using Student’s t test. 
The other P values were calculated using one-way analysis of variance followed by Dunnett’s two-tailed test, and 
P values of less than 0.05 were considered statistically significant.
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